David Goodman-Meza
Overview
Explore the profile of David Goodman-Meza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avra T, Nelson A, Friedman J, Limbach W, Sarkisian M, Nesley T, et al.
Subst Use Addctn J
. 2025 Feb;
:29767342251313595.
PMID: 39912420
Background: Substance use disorders (SUD) are a significant public health challenge, necessitating that clinicians are trained in SUD treatment and harm reduction (HR) strategies. Despite this, no studies have assessed...
2.
Samuels E, Rosen A, Speener M, Kaleekal J, Kalmin M, Goodman-Meza D, et al.
Am J Public Health
. 2024 Jun;
114(9):874-878.
PMID: 38935888
Since April 2019, CA Bridge has worked with emergency departments (EDs) in diverse geographic and emergency care settings across California to scale up low-threshold buprenorphine access, patient navigation programs, harm...
3.
McKetin R, Degan T, Saunders L, Nguyen L, Dore G, Shoptaw S, et al.
Trials
. 2024 Jun;
25(1):408.
PMID: 38907288
Background: There are no approved pharmacotherapies for methamphetamine use disorder. Two preliminary phase 2 randomised controlled trials have found mirtazapine, a tetracyclic antidepressant, to be effective in reducing methamphetamine use....
4.
Smith L, Perez-Brumer A, Nicholls M, Harris J, Allen Q, Padilla A, et al.
Implement Sci
. 2024 Jun;
19(1):39.
PMID: 38831415
Background: HIV burden in the US among people who inject drugs (PWID) is driven by overlapping syndemic factors such as co-occurring health needs and environmental factors that synergize to produce...
5.
Sundaram G, Sato T, Goodman-Meza D, Haddad M, Thakarar K, Feinberg J, et al.
J Subst Use Addict Treat
. 2024 May;
164:209392.
PMID: 38735482
People with substance use disorder (SUD) face barriers to prevention and treatment services, increasing risk for hospitalization and death. Injection drug use (IDU) can lead to an increased risk of...
6.
Shover C, Friedman J, Romero R, Jimenez S, Beltran J, Garcia C, et al.
Int J Drug Policy
. 2024 May;
:104397.
PMID: 38729890
Background: The United States (US) is an extreme global outlier for drug-related death rates. However, data describing drug-related deaths are generally available only on an 8-13-month lag. Furthermore, granular details...
7.
Scialli A, Saab S, Salimian A, Bhattacharya D, Goodman-Meza D
J Prim Care Community Health
. 2024 May;
15:21501319241253521.
PMID: 38727179
Introduction: Despite national goals to eliminate Hepatitis C (HCV) and the advancement of curative, well-tolerated direct-acting antiviral (DAAs) regimens, rates of HCV treatment have declined nationally since 2015. Current HCV...
8.
Arredondo Sanchez Lira J, Goodman-Meza D
Am J Public Health
. 2024 May;
114(6):590-592.
PMID: 38718336
No abstract available.
9.
Avra T, Cowan A, Friedman J, Fukushima J, Nelson A, Truman K, et al.
Acad Med
. 2024 Feb;
99(6):613-617.
PMID: 38412474
Problem: Stigma in health care toward people who inject drugs (PWID) is a well-described, significant barrier to quality care, resulting in poor health outcomes. Harm reduction offers a person-centered counter-framework...
10.
Goodman-Meza D, Goto M, Salimian A, Shoptaw S, Bui A, Gordon A, et al.
Open Forum Infect Dis
. 2024 Feb;
11(2):ofae030.
PMID: 38379573
Introduction: Initiation of medications for opioid use disorder (MOUD) within the hospital setting may improve outcomes for people who inject drugs (PWID) hospitalized because of an infection. Many studies used...